DNA Topoisomerase I-Targeted Therapy for Breast Cancer
Abstract
Camptothecin analogues have been developed that show enhanced pre-clinical activity against breast cancer cells. These analogues have been synthesized with two fundamental modifications that aid in their effectiveness against breast cancer: (1) they have a glycinate ester of the 20(S)-OH group, which aids in both solubility and stabilization of the drug's lactone ring; and (2) they possess a 9-chloro substitution, which allows them to covalently link to DNA. We have studied the activity of these compounds against breast cancer cells in a series of in vitro tests: growth inhibitory activity, clonogenic survival assays, and inhibition of topoisomerase I catalytic activity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 1997
- Accession Number
- ADB225820
Entities
People
- Daniel D. Von Hoff
- Shi-fon Chen